Scientists Advocate Multi-Target Alzheimer’s Treatments Over Single-Target Approaches

Alzheimer’s disease (AD) is increasingly viewed as a multifaceted condition, with recent scientific research challenging the traditional focus on singular pathological mechanisms such as amyloid-beta (Aβ) plaques or tau protein tangles. A study published in Science China Life Sciences by Professor Yan-Jiang Wang and colleagues highlights that AD arises from a convergence of genetic, aging-related, and systemic factors. This perspective shifts the emphasis from single-target therapies to integrated strategies that address multiple disease mechanisms simultaneously. The limited success of monotherapies like lecanem, donanemab—despite their ability to slow cognitive decline—underscores the shortcomings of reductionist approaches. Emerging evidence supports the development of treatments targeting Aβ, tau, genetic risk factors, aging, and systemic health in parallel.

Oral Therapies and Lifestyle Interventions Show Promise

At the International Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) conference in Copenhagen, Denmark, researchers emphasized the potential of oral therapies such as blarcamesine, which activates the brain’s clearance mechanisms to remove toxic Aβ. A Phase IIb/III trial reported that blarcames, reduced cognitive decline by 50% over 33 months without significant adverse effects, marking a departure from injectable monoclonal antibodies. Concurrently, the World Wide FINGERS (WW-FINGERS) study demonstrated that multi-domain lifestyle interventions—including diet, exercise, social engagement, and cognitive training—can lower Alzheimer’s risk over decades. With over 20,000 participants across 73 countries, the study builds on the original FINGER trial, which found that adherence to lifestyle changes improved cognitive outcomes compared to baseline after 7–11 years of follow-up.

Genetic Risk Factors and Their Role in Alzheimer’s

Genetic factors play a critical role in Alzheimer’s susceptibility. The APOE ε4 allele, the most significant genetic risk factor, increases the likelihood of late-onset AD by 3–4 times for individuals with one copy and 8–12 times for those with two. APOE ε4 prevalence in the general population is approximately 14%, but it is present in 37–65% of Alzheimer’s patients, with risk varying by ancestry. Other genetic variants, such as those in SORL1 and TOMM40, also contribute to risk, though their mechanisms remain under investigation. Early-onset familial Alzheimer’s, accounting for ~5% of cases, is linked to mutations in APP, PSEN1, and PSEN2, which are highly penetrant.

Exploring Gene Therapies for Genetic Contributors

Gene therapies are being explored to address these genetic contributors. Techniques like CRISPR/Cas9 and antisense oligonucleotides are being tested to modify APOE or APP/PSEN genes, aiming to reduce harmful protein production. For example, Alzheon’s ALZ-801 (valiltramiprosate) showed improved dementia test results in clinical trials targeting APOE4 carriers. However, no gene therapies are currently FDA-approved, and ethical concerns about germline editing persist. While genetic testing can identify risk factors, it remains a tool for early intervention rather than a cure.

Aging and the Role of Senolytic Therapies

Aging is the most significant risk factor for Alzheimer’s, with declines in mitochondrial function, cellular damage accumulation, and DNA repair mechanisms contributing to neurodegeneration. Senolytic therapies, which target senescent cells—cells that secrete inflammatory factors—are gaining attention. These therapies may improve brain health by clearing aged glial cells, which could exacerbate inflammation and neurodegeneration. Preclinical studies suggest senolytics might reduce amyloid-beta accumulation and tau pathology, though human trials are in early stages. Systemic inflammation and metabolic dysfunction, such as insulin resistance and hypertension, are also linked to cognitive decline. Drugs like dasatinib and quercetin have shown promise in animal models, but their efficacy in humans remains unproven.

The Gut-Brain Axis and Systemic Health Interventions

The gut-brain axis is increasingly recognized as a therapeutic target. Research indicates that gut microbes and inflammatory signals, including amyloid-beta and tau, can influence the brain via the nervous system, worsening neurodegeneration. This has led to investigations into diabetes medications and microbiome-modulating therapies. For instance, liraglutide, a drug used for type 2 diabetes, has shown potential in reducing amyloid-beta accumulation in preclinical studies. Systemic health interventions, such as Mediterranean diets, physical activity, and cognitive training, are also being explored to address comorbidities linked to Alzheimer’s. AI-driven tools are being developed to analyze large datasets and identify personalized treatment strategies, reflecting the growing understanding that Alzheimer’s is a complex interplay of biological, environmental, and lifestyle factors.

Interdisciplinary Collaboration and the Path Forward

The scientific community is advocating for interdisciplinary collaboration to address Alzheimer’s. The review by Wang et al. underscores the need for integrated strategies combining human iPSC-derived organoids for drug testing and precision medicine based on early biomarkers like plasma pTau217. These approaches enable earlier diagnosis and targeted interventions. The AD/PD conference also highlighted the potential of AI in drug development, clinical care, and trial recruitment, suggesting technology will play a critical role in future treatments. Despite these advances, challenges remain, including the complexity of the disease, ethical, financial, and logistical barriers. However, the convergence of genetic research, senolytic therapies, lifestyle interventions, and AI-driven analytics offers a pathway toward making Alzheimer’s a manageable or preventable condition. As the global population ages, the urgency to adopt a holistic, multi-target approach has never been greater.